Efficacy of a slow-release formulation of lanreotide (Autogel) [amount hidden]) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study

What Was Tested

This clinical trial, phase iii paper looks at Octreotide and Somatostatin.

DESIGN PATIENTS AND INTERVENTION: A phase III multicentre Italian open clinical study of 23 acromegalic patients (15 female, 8 male).

All patients had received o-LAR for 6-18 months and, after 3 months wash out, ATG120 was given every 6 weeks for a total of four injections (Period 1).

Then the interval between ATG120 injections was adjusted according to three different schemes: every 4, 6 or 8 weeks depending on GH levels (GH > 2.5 microg/l; 1 < GH <or= 2.5 microg/l; GH <or= 1 microg/l, respectively).

Who Took Part

According to the abstract, 23 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a multicenter study.

Running at several centres spread the Octreotide study over different clinics and patient groups.

The methods mention a period of 3 months.

What Was Measured

Topics PubMed links to this paper include Acromegaly, Analysis of Variance, Carrier Proteins, Glycoproteins, Growth Hormone, Insulin Resistance and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a multicenter study of Octreotide and Somatostatin in 23 patients over 3 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (Clinical endocrinology), a journal based in England.

More context: the Octreotide compound page and the Somatostatin compound page.